Penumbra Inc
PEN
Company Profile
Business description
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
Contact
One Penumbra Place
AlamedaCA94502
USAT: +1 510 748-3200
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
4,500
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
Expense guidance changes short-term earnings but not long-term fundamentals.
stocks
Chart of the Week: Australian asset managers face structural pressure
Read the latest take from our analysts.
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
From cloud computing growth to AI monetization, here’s what we’re looking for in Alphabet’s upcoming earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.10 | 54.20 | -0.59% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,944.37 | 117.46 | 0.42% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,274.71 | 84.00 | -0.16% |
| NZX 50 Index | 13,328.45 | 84.42 | -0.63% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,883.00 | 40.20 | -0.45% |
| SSE Composite Index | 4,148.75 | 2.49 | -0.06% |